About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Brca1tm1Brn
targeted mutation 1, Anton Berns
MGI:3696057
Summary 10 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Brca1tm1Brn/Brca1tm1Brn involves: 129P2/OlaHsd MGI:3696695
cn2
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd MGI:3696696
cn3
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N MGI:5617496
cn4
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N MGI:3762188
cn5
Brca1tm1Brn/Brca1tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N MGI:3762189
cn6
Brca1tm1Brn/Brca1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N MGI:3762186
cn7
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * BALB/cJ * FVB/N MGI:3762187
cn8
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N MGI:5617499
cn9
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * C57BL/6J * FVB/N MGI:5307257
cn10
Brca1tm1Brn/Brca1tm1.1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
involves: 129P2/OlaHsd * C57BL/6J * FVB/N MGI:5307256


Genotype
MGI:3696695
cn1
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• after adenoviral cre infection, OSE cells in culture show significantly higher sensitivity to cisplatin treatment compared to control cells (47.3% remain ater 48 hours compared to 66.2% of control cells remaining)
• cultured cre-infected ovarian surface epithelium (OSE) cells show slower growth than GFP-injected cells at 96 and 120 hours post injection; at 120 hours, cell numbers are decreased by 40% compared to controls

endocrine/exocrine glands
• after adenoviral-cre-mediated recombination in the ovarian surface epithelium, significantly greater morphological changes are observed compared to controls receiving adenoviral GFP injection
• there a 4-fold more epithelial invaginations in cre-injected ovaries than in GFP-injected controls at 240 days post-injection

reproductive system
• after adenoviral-cre-mediated recombination in the ovarian surface epithelium, significantly greater morphological changes are observed compared to controls receiving adenoviral GFP injection
• there a 4-fold more epithelial invaginations in cre-injected ovaries than in GFP-injected controls at 240 days post-injection




Genotype
MGI:3696696
cn2
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (239 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• after adenoviral cre treatment, double mutant OSE cells show significantly enhanced proliferation compared to control cells




Genotype
MGI:5617496
cn3
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm2Tyj
Genetic
Background
involves: 129P2/OlaHsd * 129S4/SvJae * C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (239 available)
Trp53tm2Tyj mutation (4 available); any Trp53 mutation (239 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs
• distant metastases are seen in the pleura of 87.5%, in the lung of 83% and in the liver of 46% of mutants intrabursally injected with Ad-cre that develop stage IV disease
• 2% of mice intrabursally injected with Ad-cre exhibit transformation of the oviduct epithelium, with lesions ranging from atypical hyperplasia, to carcinoma in situ to adenocarcinoma

reproductive system
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs
• 2% of mice intrabursally injected with Ad-cre exhibit transformation of the oviduct epithelium, with lesions ranging from atypical hyperplasia, to carcinoma in situ to adenocarcinoma
• oviduct lesions are characterized by a glandular/acinar histology

homeostasis/metabolism
• ovaries in intrabursally Ad-cre injected mice show hemorrhagic or serous ascites

endocrine/exocrine glands
• 70% of mice injected with a cre-expressing adenovirus (Ad-cre) under the bursa develop serous epithelial ovarian cancer pathology
• ovarian surface epithelium carcinomas that develop in mice intrabursally injected with Ad-cre show a range of morphologic patterns including papillary, micropapillary/filigree, microcystic, poorly differentiated adenocarcinoma, and solid/undifferentiated
• mice develop multifocal peritoneal carcinomatosis with tumor spread to all abdominal organs

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
ovarian cancer DOID:2394 OMIM:167000
OMIM:607893
J:189304




Genotype
MGI:3762188
cn4
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
Genetic
Background
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(KRT14-cre)8Brn mutation (4 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (239 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• mice develop mammary gland with a latency of 213 days
• 80% of mice develop tumors compared to 63% of Trp53tm1Jjon/Trp53tm1Jjon Tg(KRT14-cre)8Jjon mice
• mice develop mammary types of carcinoma (91%), biphasic carcinoma that is poorly defined (3%) and biphasic carcinoma that is well defined (6%)

integument
• mice develop mammary gland with a latency of 213 days
• 80% of mice develop tumors compared to 63% of Trp53tm1Jjon/Trp53tm1Jjon Tg(KRT14-cre)8Jjon mice
• mice develop mammary types of carcinoma (91%), biphasic carcinoma that is poorly defined (3%) and biphasic carcinoma that is well defined (6%)

endocrine/exocrine glands
• mice develop mammary gland with a latency of 213 days
• 80% of mice develop tumors compared to 63% of Trp53tm1Jjon/Trp53tm1Jjon Tg(KRT14-cre)8Jjon mice
• mice develop mammary types of carcinoma (91%), biphasic carcinoma that is poorly defined (3%) and biphasic carcinoma that is well defined (6%)

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:126551




Genotype
MGI:3762189
cn5
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Tg(KRT14-cre)8Brn/0
Genetic
Background
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(KRT14-cre)8Brn mutation (4 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
N
• mice fail to develop mammary gland tumors over 800 days of observation




Genotype
MGI:3762186
cn6
Allelic
Composition
Brca1tm1Brn/Brca1+
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
Genetic
Background
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(KRT14-cre)8Brn mutation (4 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (239 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• mice develop mammary gland with a latency of 332 days

integument
• mice develop mammary gland with a latency of 332 days

endocrine/exocrine glands
• mice develop mammary gland with a latency of 332 days

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:126551




Genotype
MGI:3762187
cn7
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53+
Tg(KRT14-cre)8Brn/0
Genetic
Background
involves: 129P2/OlaHsd * BALB/cJ * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(KRT14-cre)8Brn mutation (4 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (239 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• mice develop mammary gland with a latency of 407 days

integument
• mice develop mammary gland with a latency of 407 days

endocrine/exocrine glands
• mice develop mammary gland with a latency of 407 days

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:126551




Genotype
MGI:5617499
cn8
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Tg(Krt18-EGFP,-TAg121)36Ysng/0
Trp53tm1Brn/Trp53tm1Brn
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(Krt18-EGFP,-TAg121)36Ysng mutation (0 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (239 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• 78% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

reproductive system
• 78% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

endocrine/exocrine glands
• 78% of mice injected with a cre-expressing adenovirus under the bursa develop serous epithelial ovarian cancer pathology

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
ovarian cancer DOID:2394 OMIM:167000
OMIM:607893
J:189304




Genotype
MGI:5307257
cn9
Allelic
Composition
Brca1tm1Brn/Brca1tm1Brn
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6J * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(KRT14-cre)8Brn mutation (4 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (239 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• compared to KB1C61GP littermate controls
• most mammary tumors are poorly differentiated solid carcinomas
• a small percentage of tumors are classified as carcinosarcomas or lumen forming carcinomas
• compared to KB1C61GP littermate controls
• in transplanted tumors response to olaparib treatment is improved compared to KB1C61GP littermate controls and KP mice
• transplanted tumors never develop resistance to cisplatin unlike tumors from KP mice
• increased genomic instability in tumors compared to mice homozygous for Trp53tm1Brn and carrying Tg(KRT14-cre)8Brn (KP mice)
• median latency is 236 days compared to 197 days in littermate controls heterozygous for Brca1tm1Brn and Brca1tm1.1Jjon, homozygous for Trp53tm1Brn and carrying Tg(KRT14-cre)8Brn (KB1C61GP)

integument
• compared to KB1C61GP littermate controls
• most mammary tumors are poorly differentiated solid carcinomas
• a small percentage of tumors are classified as carcinosarcomas or lumen forming carcinomas
• compared to KB1C61GP littermate controls

endocrine/exocrine glands
• compared to KB1C61GP littermate controls
• most mammary tumors are poorly differentiated solid carcinomas
• a small percentage of tumors are classified as carcinosarcomas or lumen forming carcinomas

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:178595




Genotype
MGI:5307256
cn10
Allelic
Composition
Brca1tm1Brn/Brca1tm1.1Jjon
Trp53tm1Brn/Trp53tm1Brn
Tg(KRT14-cre)8Brn/0
Genetic
Background
involves: 129P2/OlaHsd * C57BL/6J * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Brca1tm1.1Jjon mutation (0 available); any Brca1 mutation (114 available)
Brca1tm1Brn mutation (2 available); any Brca1 mutation (114 available)
Tg(KRT14-cre)8Brn mutation (4 available)
Trp53tm1Brn mutation (18 available); any Trp53 mutation (239 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• compared to KB1P littermate controls homozygous
• most mammary tumors are poorly differentiated solid carcinomas
• a small percentage of tumors are classified as carcinosarcomas or lumen forming carcinomas
• markedly lower incidence compared to KB1P littermate controls
• in transplanted tumors response to olaparib treatment is impaired compared to KB1P littermate controls but better than in KP mice
• transplanted tumors develop resistance to cisplatin and survival of transplanted mice is worse than that of mice transplanted with tumors from KB1P mice
• increased genomic instability in tumors compared to mice homozygous for Trp53tm1Brn and carrying Tg(KRT14-cre)8Brn (KP mice)
• median latency is 197 days compared to 236 days in littermate controls homozygous for Brca1tm1Brn Trp53tm1Brn and carrying Tg(KRT14-cre)8Brn (KB1P)
• however, no difference in the latency of mammary tumor development

integument
• compared to KB1P littermate controls homozygous
• most mammary tumors are poorly differentiated solid carcinomas
• a small percentage of tumors are classified as carcinosarcomas or lumen forming carcinomas
• markedly lower incidence compared to KB1P littermate controls

endocrine/exocrine glands
• compared to KB1P littermate controls homozygous
• most mammary tumors are poorly differentiated solid carcinomas
• a small percentage of tumors are classified as carcinosarcomas or lumen forming carcinomas

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
breast cancer DOID:1612 OMIM:114480
J:178595





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
10/29/2024
MGI 6.24
The Jackson Laboratory